ProMIS Neurosciences Q2 net loss widens
PMN•Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
- Wall Street's median 12-month price target for ProMIS Neurosciences Inc is $35.00, about 141.4% above its August 12 closing price of $14.50
Q2 net loss widens
- US biotechnology firm's Q2 net loss widened yr/yr
- Cash and short-term investments rose to $53.4 million, funding operations through 2027
- Company reported positive blinded six-month interim safety and biomarker results from Phase 1b PRECISE-AD trial
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net Loss | $11.70 million |
Trial progress and outlook
- Company expects to report unblinded 12-month topline PRECISE-AD data in Q1 2027
